Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617414 | 0.74 | ALDH1A1 (0.33) | SCN4AIDO1ALDH1A1 | |
| SCHEMBL28799980 | 0.71 | SCN4A (0.44) | SCN4AIDO1NPC1RAB9APDPK1 | |
| SCHEMBL1521918 | 0.71 | — | — | |
| SCHEMBL12984925 | 0.70 | — | — | |
| SCHEMBL3068150 | 0.69 | SCN4A (0.62) | SCN4AIDO1NPC1RAB9APDPK1 | |
| SCHEMBL115447 | 0.69 | CYP3A4 (0.33) | SMN1; SMN2 | |
| SCHEMBL1226376 | 0.69 | IDO1 (0.52) | SCN4AIDO1NPC1RAB9APDPK1 | |
| SCHEMBL1585080 | 0.68 | NOTUM (0.43) | SCN4AIDO1NPC1RAB9APDPK1 | |
| SCHEMBL3026361 | 0.67 | SCN4A (1.00) | SCN4AIDO1NPC1RAB9APDPK1 | |
| SCHEMBL496792 | 0.67 | HDAC1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | claimed |
| EP-2914589-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - Science Park S.p.A. (IT) | 2015-09-09 | — | — | EP | claimed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | claimed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| CN-105164124-A | Compounds and compositions for treating parasitic diseases | NOVARTIS AG | 2015-12-16 | — | — | CN | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1539159-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | SCN4A 4739/4885IDO1 1382/4885NPC1 1330/4885 |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | SCN4A 3253/4885IDO1 189/4885NPC1 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.